Jim Mel­lon's Ju­ve­nes­cence takes a chance on tiny up­start run by for­mer Pfiz­er ex­ec

When Mar­garet Jack­son was do­ing some con­sult­ing work for Ju­ve­nes­cence CEO Greg Bai­ley last year, she did not an­tic­i­pate the an­ti-ag­ing biotech ven­ture would even­tu­al­ly in­vest in her new­ly in­cor­po­rat­ed pre­clin­i­cal meta­bol­ic dis­ease biotech BY­OMass.

The com­pa­ny, run by Jack­son who is the on­ly full-time em­ploy­ee, has been in stealth mode — it is so ear­ly stage, it doesn’t even have a web­site yet.

Ju­ve­nes­cence on Wednes­day said it had pledged up to $6.5 mil­lion in eq­ui­ty fi­nanc­ing in BY­OMass and will col­lab­o­rate with the com­pa­ny to de­vel­op ther­a­peu­tics de­signed to mod­u­late me­tab­o­lism as­so­ci­at­ed with ag­ing and age-re­lat­ed chron­ic ill­ness­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER